[
    [
        {
            "time": "",
            "original_text": "康泰生物：全球首款双载体13价肺炎疫苗获批上市",
            "features": {
                "keywords": [
                    "康泰生物",
                    "双载体",
                    "13价肺炎疫苗",
                    "获批上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：全球首款双载体13价肺炎疫苗获批上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "山西证券：给予康泰生物增持评级",
            "features": {
                "keywords": [
                    "山西证券",
                    "康泰生物",
                    "增持评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "山西证券：给予康泰生物增持评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "山西证券维持康泰生物增持评级：新冠疫苗带动三季度业绩，13价肺炎疫苗获批准上市",
            "features": {
                "keywords": [
                    "山西证券",
                    "康泰生物",
                    "新冠疫苗",
                    "三季度业绩",
                    "13价肺炎疫苗",
                    "获批上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "山西证券维持康泰生物增持评级：新冠疫苗带动三季度业绩，13价肺炎疫苗获批准上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "太平洋维持康泰生物买入评级：Q3业绩高速增长，重磅品种13价肺炎疫苗获批准，放量可期",
            "features": {
                "keywords": [
                    "太平洋",
                    "康泰生物",
                    "Q3业绩",
                    "高速增长",
                    "13价肺炎疫苗",
                    "放量可期"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "太平洋维持康泰生物买入评级：Q3业绩高速增长，重磅品种13价肺炎疫苗获批准，放量可期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "德邦证券：给予康泰生物买入评级，目标价位158.2元",
            "features": {
                "keywords": [
                    "德邦证券",
                    "康泰生物",
                    "买入评级",
                    "目标价位"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "德邦证券：给予康泰生物买入评级，目标价位158.2元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物前三季净利润大增139% 研发投入“节节攀升”",
            "features": {
                "keywords": [
                    "康泰生物",
                    "前三季",
                    "净利润",
                    "大增139%",
                    "研发投入",
                    "节节攀升"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物前三季净利润大增139% 研发投入“节节攀升”",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "钛媒体科股早知道：“双11”预售正式启动，头部网红单日销售额超100亿元；全国累计接种新冠疫苗超22亿剂次",
            "features": {
                "keywords": [
                    "双11",
                    "预售",
                    "头部网红",
                    "销售额",
                    "新冠疫苗",
                    "接种",
                    "22亿剂次"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费",
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "钛媒体科股早知道：“双11”预售正式启动，头部网红单日销售额超100亿元；全国累计接种新冠疫苗超22亿剂次",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]